Ma huang associated acute liver failure requiring liver transplantation

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 5, 2005, Pages 581-584

  Skoulidis, Ferdinandos ^a,b   Alexander, Graeme J M ^a   Davies, Susan E ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Acute liver failure; Chinese herbal medicine; Ephedra; Ma huang; Transplantation

Indexed keywords

CORDYCEPS SINENSIS EXTRACT; EPHEDRA SINICA EXTRACT; HERBA SELLAGINELLA EXTRACT; HERBA SENECIONIS SCANDENTIS EXTRACT; HERBACEOUS AGENT; RADIX AULICAE DAHURICAE EXTRACT; RHIZOMA CHUANXIONG EXTRACT; SEMEN CASSIAE EXTRACT; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHINESE MEDICINE; CLINICAL FEATURE; DISEASE COURSE; EPHEDRA SINICA; FEMALE; HERBA SELLAGINELLA; HERBA SENECIONIS SCANDENTIS; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RADIX AULICAE DAHURICAE; RHIZOMA CHUANXIONG; SEMEN CASSIAE; SINUSITIS;

DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MIDDLE AGED; PLANT PREPARATIONS;

EID: 17844402272     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200505000-00017     Document Type: Article

References (17)

1. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445.
2. Seef LB, Lindsay KL, Bacon BR. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34:595-603.
3. Eisenberg DM, Kessler RC, Van Rompay MI. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001; 135:344-351.
4. Nadir A, Agrawal S, King P, King PD, Marshall JB. Acute hepatitis associated with the use of a chinese herbal product, Ma huang. Am J Gastoenterol 1996; 91:1436-1438.
5. Medicines Control Agency. Safety of Herbal Medicinal Products. July 2002. Report number 72002. Available on: http://www.mca.gov.uk/ourwork/licencingmeds/ herbalsafetyreport72002.pdf
6. Mattocks AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids. New York: Academic Press; 1986.
7. Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in Perspective - a current review. Phytotherapy Res 2003; 17:703-712.
8. Loo AG, Stock MJ. Ephedrine as a thermogenic drug. Int J Obesity 1993; 17(suppl):S1-S2.
9. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing Ephedra alkaloids. N Engl J Med 2000; 343:1833-1838.
10. Boeth JM, Cadey CF. Possible case of mania associated with Ma huang. Pharmacotherapy 2003; 23:380-383.
11. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol 1999; 37:485-489.
12. Powell T, Hsu FF, Turk J, Hruska K. Ma huang strikes again: Ephedrine nephrolithiasis. Am J Kidney Dis 1998; 32:153-159.
13. US Food and Drug Administration. Dietary supplements containing ephedra alkaloids: proposed rule, 62. Federal Register 1997; 30678-30724.
14. US Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Federal Register 2004(Feb 11); 69(28):6787-6854.
15. Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of Ma huang [Letter]. Am J Gastroenterol 2001; 96:1654-1655.
16. Bajaj J, Knox JF, Komorowski R, Saeian K. The irony of herbal hepatitis. Ma-huang induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Dig Dis Sci 2003; 48:1925-1928.
17. Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138:852-858.